ArticleLab on a chip2012
Thick-tissue bioreactor as a platform for long-term organotypic culture and drug delivery.
Article in Lab on a chip, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Quantifying and modeling loss of estrogen and progesterone in PDMS-based devices.Microfluidics and nanofluidics · 2025Article
- Relationship between Adsorption and Toxicity of Nephrotoxic Drugs in Microphysiological Systems (MPS).Micromachines · 2023Article
- FutureTox IV Workshop Summary: Predictive Toxicology for Healthy Children.Toxicological sciences : an official journal of the Society of Toxicology · 2021Review
- Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential.PLoS computational biology · 2019Article
- iPSC-Derived Brain Endothelium Exhibits Stable, Long-Term Barrier Function in Perfused Hydrogel Scaffolds.Stem cell reports · 2019Article
- Chemical-PDMS binding kinetics and implications for bioavailability in microfluidic devices.Lab on a chip · 2019Article
- Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment.Biomicrofluidics · 2018Article
- Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.Journal of the Royal Society, Interface · 2018Review
- Management and potentialities of primary cancer cultures in preclinical and translational studies.Journal of translational medicine · 2017Review
- Programming microphysiological systems for children's health protection.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- Advances in multicellular spheroids formation.Journal of the Royal Society, Interface · 2017Review
- Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells.Frontiers in bioengineering and biotechnology · 2017Review
- Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit.Journal of neuroinflammation · 2016Article
- Microfluidic-Based Multi-Organ Platforms for Drug Discovery.Micromachines · 2016Review
- Article
- Variation in diffusion of gases through PDMS due to plasma surface treatment and storage conditions.Biomedical microdevices · 2014Article
- Micro total analysis systems: fundamental advances and biological applications.Analytical chemistry · 2014Review
- Engineering challenges for instrumenting and controlling integrated organ-on-chip systems.IEEE transactions on bio-medical engineering · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We have developed a novel, portable, gravity-fed, microfluidics-based platform suitable for optical interrogation of long-term organotypic cell culture. This system is designed to provide convenient control of cell maintenance, nutrients, and experimental reagent delivery to tissue-like cell densities housed in a transparent, low-volume microenvironment. To demonstrate the ability of our Thick-Tissue Bioreactor (TTB) to provide stable, long-term maintenance of high-density cellular arrays, we observed the morphogenic growth of human mammary epithelial cell lines, MCF-10A and their invasive variants, cultured under three-dimensional (3D) conditions inside our system. Over the course of 21 days, these cells typically develop into hollow "mammospheres" if cultured in standard 3D Matrigel. This complex morphogenic process requires alterations in a variety of cellular functions, including degradation of extracellular matrix that is regulated by cell-produced matrix proteinases. For our "drug" delivery testing and validation experiments we have introduced proteinase inhibitors into the fluid supply system, and we observed both reduced proteinase activity and inhibited cellular morphogenesis. The size inhibition results correlated well with the overall proteinase activities of the tested cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.